Title:
ジペプチジルペプチダーゼ-IV阻害剤および抗糖尿病薬剤を含む組合せ物
Document Type and Number:
Japanese Patent JP6374995
Kind Code:
B2
Abstract:
The invention relates to a combination which comprises a DPP-IV inhibitor (preferably NVP LAF237 (vildagliptin) or NVP-DPP728) and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phopshate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, ±-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and ± 2 -adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions such as type 2 diabetes mellitus, impaired glucose tolerance (IGT), impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis.
Inventors:
Berg Balkan
Thomas Edward Hughes
David Grenville Holmes
Edwin Bernard Bihlhower
Thomas Edward Hughes
David Grenville Holmes
Edwin Bernard Bihlhower
Application Number:
JP2017007638A
Publication Date:
August 15, 2018
Filing Date:
January 19, 2017
Export Citation:
Assignee:
Novartis Age
International Classes:
A61K31/40; A61K31/00; A61K31/155; A61K31/198; A61K31/4025; A61K31/427; A61K31/44; A61K31/4439; A61K31/4453; A61K31/505; A61K31/64; A61K31/7036; A61K45/06; A61P3/00; A61P3/04; A61P3/10; A61P19/02; A61P19/10; A61P29/00; A61P43/00
Foreign References:
| WO1999038501A2 | ||||
| WO1999061431A1 | ||||
| WO2000034241A1 |
Other References:
PAULY,R.P. et al.,"Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor ile-thiazolidide",Metabolism,1999年 3月,Vol.48,No.3,P.385-389
DEACON, C.F. et al.,"Dipeptidyl Peptidase IV "Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig",Diabetes,1998年 5月,Vol.47,No.5,P.764-769
DEACON, C.F. et al.,"Dipeptidyl Peptidase IV "Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig",Diabetes,1998年 5月,Vol.47,No.5,P.764-769
Attorney, Agent or Firm:
Hiroshi Kobayashi
Norio Omori
Mami Hino
Yasuhito Suzuki
Norio Omori
Mami Hino
Yasuhito Suzuki